What Happened? Shares of biotech company Vertex Pharmaceuticals (NASDAQ:VRTX) jumped 3.8% in the afternoon session after Wolfe Research upgraded the stock from "Peer Perform" to "Outperform" and ...

The recommendations of Wall Street analysts are often relied on by investors when deciding whether to buy, sell, or hold a ...

Vertex Pharmaceutical (VRTX) stock gains as RBC Capital Markets upgrades the company to Outperform, citing a durable cystic ...

Vertex Pharmaceuticals stock (NASDAQ: VRTX) is trending higher after the U.S. FDA approved Journavx – an oral non-opioid pain medication. This is a big win for Vertex, given that Journavx can ...

Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $508.25, ...

Vertex Pharmaceuticals is scheduled to post its fourth-quarter results soon, and analysts project a double-digit earnings ...

Shares of Vertex Pharmaceuticals (NASDAQ: VRTX) were sinking 11.9% as of 10:18 a.m. ET on Tuesday. The sharp decline came after the company announced its 2025 first-quarter results on Monday evening.

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) is one of the best future stocks to buy for the long term. On January 12, ...

Vertex Pharmaceuticals stock declined almost 13% in six months due to poor test results for a new drug. When it comes to the drug and biotech sector, a major pipeline setback can hit the stock hard.

Vertex Pharmaceuticals Inc. (NASDAQ: VRTX) shares are trending on Thursday. Shares of the Massachusetts-based biotech company, which gained 4.31% during Wednesday's regular session, tapered down 0.21% ...

It's the first new class of pain treatment approved in more than 20 years, Vertex says. Shares of Vertex Pharmaceuticals Inc. surged ahead of Friday's market open after the Food and Drug ...